Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 9 NIH 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms, Second Primary 1 Neoplasms 1

Interventions

Cyclophosphamide 388 Specimen Handling 377 Magnetic Resonance Spectroscopy 328 Radiotherapy 306 Biopsy 273 Cisplatin 258 Carboplatin 255 Paclitaxel 235 Doxorubicin 226 Fluorouracil 200 Etoposide 197 Vincristine 183 Bevacizumab 181 Filgrastim 170 Gemcitabine 163 Leucovorin 149 Cytarabine 144 aldesleukin 141 Taxes 127 Docetaxel 122 Chemotherapy, Adjuvant 114 Oxaliplatin 113 fludarabine phosphate 111 Methotrexate 108 Rituximab 107 Radiation 106 Bortezomib 105 Prednisone 102 Irinotecan 100 Dexamethasone 100

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

NIH × Clonidine × Clear all

NCT00166686 2013-01-11

Clonidine for Neurocognitive Sequelae

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Phase 1/2 Withdrawn

Neoplasms, Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡